MADISON, Wis. - Exact Sciences Corp. (NASDAQ: NASDAQ:EXAS), known for its cancer screening and diagnostic tests, has revealed study results indicating advancements in multi-cancer early detection (MCED) testing. Research presented at the American Association for Cancer Research Special Conference in San Diego showcases a new multi-biomarker approach that has shown to improve the detection of cancer, particularly in its early stages.
The company's studies suggest that utilizing a test that combines DNA mutation analysis with methylation and protein markers – a method referred to as MP-r – can significantly increase the sensitivity for detecting stage I and II cancers. For instance, the sensitivity for stage I cancers rose by 28% when breast and prostate cancers were excluded from the analysis. Overall, the MP-r approach demonstrated a 5% improvement in sensitivity across all cancer stages.
Moreover, modeling data proposes that incorporating MCED testing into standard screening practices could potentially decrease the occurrence of stage IV cancers by 42% and reduce cancer mortality by 17% over a decade. This is seen as a critical step given that cancer is projected to become the leading cause of death in the U.S. by 2030, and currently, only about 14% of U.S. cancers are diagnosed through screening.
The DETECT-A study, which is the first prospective interventional trial of an MCED blood test, also found that adherence to lung cancer screening was not adversely affected by the addition of MCED testing.
Exact Sciences is developing the Cancerguard test, which aims to detect multiple cancers from a single blood draw. While the Cancerguard test is still under development and has not received regulatory approval, it is intended to offer high specificity to reduce false positives and simplify diagnostic pathways, potentially leading to fewer follow-up procedures.
These findings are based on a press release statement and have not been independently verified. The Cancerguard test's development goals are ambitious, and the company stresses that the test has not yet been cleared or approved by any regulatory authorities. Exact Sciences emphasizes the importance of rigorous, comprehensive approaches to multi-cancer screening to address the significant gap in patient care due to the low percentage of cancers currently detected through screening.
In other recent news, Exact Sciences Corporation reported a 13% year-over-year revenue increase in its third quarter 2024 earnings, reaching $709 million. Despite challenges such as Hurricane Helene disruptions and lower-than-expected Cologuard testing frequency, the company delivered test results to 1.2 million patients and saw a 75% increase in adjusted EBITDA to $99 million. It's worth noting that the FDA has approved the company's next-generation colorectal cancer screening test, Cologuard Plus, with a launch anticipated in the second quarter of 2025.
Exact Sciences has revised its full-year revenue guidance to between $2.73 billion and $2.75 billion, with adjusted EBITDA expected to be between $310 million and $320 million. The company's future looks promising, with optimism about growth and profitability in 2025 driven by new products and platforms. Exact Sciences also projects accelerated growth for 2025 and a strong product pipeline including Oncodetect and the ExactNexus platform.
The company aims for a 15% growth target over the next three years and a 20% adjusted EBITDA by 2027. However, it has faced commercial execution challenges, including sales staff turnover and reduced in-office visits. Despite these challenges, Exact Sciences remains confident in its strategy and execution, emphasizing its commitment to operational efficiency and capitalizing on new product offerings.
InvestingPro Insights
As Exact Sciences Corp. (NASDAQ: EXAS) advances its multi-cancer early detection (MCED) technology, investors should consider the company's financial health and market performance. According to InvestingPro data, Exact Sciences has a market capitalization of $9.49 billion and reported revenue of $2.69 billion in the last twelve months as of Q3 2023, with a revenue growth of 11.91% over the same period.
Despite the promising research results, it's important to note that Exact Sciences is not currently profitable. The company's operating income for the last twelve months stands at -$227.22 million, with a negative operating income margin of -11.27%. This aligns with an InvestingPro Tip indicating that analysts do not anticipate the company will be profitable this year.
However, the company's gross profit margin of 72.96% suggests strong potential in its core business operations, which could be crucial as it develops and commercializes new tests like Cancerguard. Another positive sign is that Exact Sciences' liquid assets exceed its short-term obligations, providing financial flexibility as it invests in research and development.
Investors should be aware that the stock has faced recent challenges, with InvestingPro data showing a 29.31% decline in the past month and an 8.33% drop in the last week. This volatility is reflected in an InvestingPro Tip suggesting that the stock's Relative Strength Index (RSI) indicates it may be in oversold territory, potentially presenting a buying opportunity for those bullish on the company's long-term prospects.
For those interested in a deeper analysis, InvestingPro offers 7 additional tips for Exact Sciences, providing a more comprehensive view of the company's financial situation and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.